LIMN Liminatus Company Short-Term Debt

Liminatus Pharma LLC - graphic logo of issuer LIMN

Liminatus Pharma (LIMN) aims for dominance in the gastrointestinal cancer therapy segment via its GCC CAR-T platform, while the company's short-term liability structure shows a figure at 0.00. A lack of sales and post-SPAC risks create financial instability. The current development vector relies on organic growth and the search for partners among academic institutions to conduct research.

LIMN liminatuspharma.com Short-Term Debt (05/02/2025 - 10/31/2026)

Analytical breakdowns and data insights for company Liminatus (LIMN)

- current quotes and average value forecast:
Price Chart Liminatus Pharma LLC|LIMN - Average Forecast Price
- market capitalization data:
Market Value Liminatus Pharma LLC|LIMN - Total Company Value
- shareholders' equity book value data:
Net Assets per Single Share Liminatus Pharma|LIMN - Total Stockholders' Equity|Market Capitalization to Book Value Ratio liminatuspharma.com|LIMN - Company Balance Sheet Assets
- company total debt and liquidity indicators:
Total Debt to Equity Ratio Liminatus Pharma|LIMN - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Liminatus Pharma|LIMN - Aggregate Debt Obligations|Debts to Book Capitalization Liminatus Pharma LLC|LIMN - Long-Term Debt Volume|Company Short-Term Debt Liminatus Pharma|Quick Liquidity liminatuspharma.com
- earnings and multiples data:
LIMN - Net Income
General company analysis:Liminatus Pharma LLC (LIMN)
Flagship merchandise of liminatuspharma.com

Analyzing the resilience of Liminatus Pharma (LIMN) to external shocks requires liquidity monitoring, particularly given the risks of raw material supply disruptions from Asia and delays in clinical trials. The dynamics of current short-term liabilities reflect the total volume of debt maturing within one year, allowing investors to assess the risk of cash flow gaps and the efficiency of debt capital management to ensure the operational reliability of the business.

Competitors of Liminatus Pharma

IBRX - Company Short-Term Debt|Short-Term Debt Immunocore Holdings|Janux Pharma (JANX) - Company Short-Term Debt|RCUS (Arcus Corp) - Company Short-Term Debt|Company Short-Term Debt Zymeworks Inc.|Short-Term Debt tangotx.com TNGX|Company Short-Term Debts IOVA|Immatics NV (IMTX) - Short-Term Indebtedness|Xencor Corp - Company Current Liabilities|Compass Therapeutics Corp (CMPX) - Short-Term Debt|REPL: Company Current Liabilities|Company Short-Term Loans and Borrowings LYEL (lyell.com)|IPHA: Company Short-Term Debts|PYXS - Short-Term Debt Volume|Company Short-Term Debt Compugen Ltd|Company Current Liabilities IO Biotech Inc. (IOBT)|Company Short-Term Debt Sutro Biopharma, Inc. (STRO)|Company Current Liabilities minktherapeutics.com INKT|Werewolf Therapeutics, Inc. - Company Current Liabilities|Company Short-Term Debts Immix Biopharma Inc. IMMX|ALXO - Company Short-Term Debt|CUE (Cue Biopharma Inc.) - Company Short-Term Indebtedness|pdsbiotech.com (PDSB) - Company Short-Term Debt|Short-Term Debt Sonnet BioTherapeutics Holdings (SONN)|Company Current Liabilities MAIA|LVTX - Short-Term Indebtedness|Company Current Liabilities NXTC (NextCure Corp)|Amount of Current Liabilities LPTX|Company Short-Term Debts INTS (Intensity Therapeutics, Inc.)|Company Short-Term Loans and Borrowings SNSE|Theriva Biologics - Company Short-Term Debts|Short-Term Debt Gritstone bio, Inc.|Kineta Bio (KA) - Company Short-Term Debt|NexImmune Corporation - Company Short-Term Loans and Borrowings|TSBX (Turnstone Biologics Corp) - Company Short-Term Debts|Company Short-Term Debts vaccinex.com|Company Short-Term Debt Harpoon Therapeutics, Inc. (HARP)